| Literature DB >> 33818145 |
Muhammad Sohaib Asghar1, Noman Ahmed Khan2, Syed Jawad Haider Kazmi3, Maira Hassan4, Uzma Rasheed4, Rumael Jawed5, Rabail Yaseen1, Syed Anosh Ali Naqvi1.
Abstract
BACKGROUND: Esophageal cancer ranks eighth among the most prevalent cancers globally and is the sixth leading cause of mortality from malignancy worldwide; it is the 7th most prevalent malignancy in males and the 6th most prevalent malignancy in females. In Pakistan, the incidence is 4.1 per 100 000 with the province of Baluchistan having the greatest incidence.Entities:
Year: 2021 PMID: 33818145 PMCID: PMC8020643 DOI: 10.5144/0256-4947.2021.91
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.526
Demographic data (n=1009).
| Variable | Frequency |
|---|---|
| Male | 443 (43.9) |
| Female | 566 (56.1) |
| Sindh | 849 (84.1) |
| Balochistan | 62 (6.1) |
| Punjab | 18 (1.8) |
| Khyber Pakhtunkhwa | 43 (4.3) |
| Gilgit Baltistan | 18 (1.8) |
| Afghanistan migrants | 16 (1.6) |
| Others | 3 (.3) |
| Sindhi | 434 (43.0) |
| Balochi | 90 (8.9) |
| Punjabi | 55 (5.5) |
| Balti | 12 (1.2) |
| Pashtoon | 108 (10.7) |
| Urdu | 259 (25.7) |
| Others | 51 (5.1) |
| Housewife | 560 (55.5) |
| Labor | 208 (20.6) |
| Farmer | 74 (7.3) |
| Government employee | 18 (1.8) |
| Private business | 58 (5.8) |
| Shopkeeper | 14 (1.4) |
| Retired | 28 (2.8) |
| Others | 49 (4.9) |
| None | 834 (82.7) |
| Diabetes mellitus | 53 (5.3) |
| Hypertension | 88 (8.7) |
| Ischemic heart disease | 31 (3.1) |
| Tuberculosis | 5 (.5) |
| Hepatitis B | 9 (.9) |
| Hepatitis C | 26 (2.6) |
| Others | 18 (1.8) |
| None | 471 (46.7) |
| Smoking (tobacco cigarettes) | 150 (14.9) |
| Hookah (smoking) | 23 (2.3) |
| Betel leaf | 128 (12.7) |
| Betel nuts | 91 (9.0) |
| Betel quid (gutka) | 90 (8.9) |
| Naswar (dipping tobacco) | 82 (8.1) |
| Alcohol | 5 (.5) |
| Other illicit drugs | 5 (.5) |
| Squamous cell carcinoma | 834 (82.7) |
| Adenocarcinoma | 175 (17.3) |
Data are number (%).
Frequency of symptomatology among the histopathological variants (n=1009).
| Clinical features | Squamous cell carcinoma (n=834) | Adenocarcinoma (n=175) | |
|---|---|---|---|
| Fever: n=25 (2.5%) | 19 (2.3%) | 6 (3.4%) | .419 |
| Weight loss: n=196 (19.4%) | 164 (19.7%) | 32 (18.3%) | .675 |
| Upper GI bleeding: n=47 (4.7%) | 41 (4.9%) | 6 (3.4%) | .396 |
| Retrosternal burning: n=60 (5.9%) | 42 (5.0%) | 18 (10.3%) | .008 |
| Acid reflux: n=22 (2.2%) | 22 (2.6%) | 0 (0.0%) | .022 |
| 260 (31.2%) | 67 (38.3%) | .068 | |
| Both solids/liquids: n=178 (17.6%) | 151 (18.1%) | 27 (15.4%) | |
| Only solids: n=41 (4.0%) | 33 (3.9%) | 8 (4.6%) | |
| Only liquids: n=16 (1.6%) | 12 (1.4%) | 4 (2.3%) | .217 |
| First solids then progressed to liquids: n=92 (9.1%) | 73 (8.7%) | 19 (10.8%) | |
| Odynophagia: n=45 (4.5%) | 45 (5.4%) | 0 (0.0%) | .002 |
| Anorexia: n=4 (0.4%) | 2 (0.2%) | 2 (1.1%) | .141 |
| Regurgitation of food: n=15 (1.5%) | 11 (1.3%) | 4 (2.3%) | .310 |
| Nocturnal cough: n=33 (3.3%) | 30 (3.6%) | 3 (1.7%) | .203 |
| Vomiting: n=230 (22.8%) | 189 (22.7%) | 41 (23.5%) | .826 |
| Projectile: (n=188) 18.6% | 155 (18.6%) | 33 (18.9%) | .933 |
| Non-projectile: (n=42) 4.2% | 34 (4.1%) | 8 (4.6%) | .766 |
| Dyspnea: n=2 (0.2%) | 1 (0.1%) | 1 (0.6%) | .317 |
| Neck swelling: n=1 (0.1%) | 1 (0.1%) | 0 (0.0%) | 1.000 |
| Halitosis: n=1 (0.1%) | 1 (0.1%) | 0 (0.0%) | 1.000 |
| No symptoms: n=46 (4.6%) | 43 (5.2%) | 3 (1.7%) | .047 |
Indicates Fisher's exact test to compute the P value.
Indicates the chi-square test used to compute the P value.
Comparison of biochemical markers among the variants of esophageal carcinoma.
| Laboratory investigations | All patients (n=1009) | Squamous cell carcinoma (n=834) | Adenocarcinoma (n=175) | |
|---|---|---|---|---|
| Hemoglobin (g/dL) | 11.0 (10.0–12.0) | 11.0 (10.0–12.0) | 12.0 (10.0–12.3) | .003 |
| Mean corpuscular volume (fL) | 80.0 (76.0–88.0) | 80.0 (76.0–88.0) | 82.0 (76.0–88.0) | .091 |
| Platelets (109 cells/liter) | 233.0 (187.0–302.0) | 237.0 (190.75–312.0) | 209.0 (167.0–267.0) | .001 |
| Total leucocyte count (109 cells/liter) | 6.3 (5.0–8.8) | 6.3 (5.0–9.0) | 6.3 (4.7–7.3) | .078 |
| Sodium (mEq/L) | 136.0 (133.0–141.0) | 136.0 (133.0–141.0) | 136.0 (134.0–141.0) | .175 |
| Potassium (mEq/L) | 4.0 (3.50–4.55) | 4.0 (3.5–4.5) | 4.0 (3.2–4.6) | .870 |
| Chloride (mEq/L) | 100.0 (98.0–102.0) | 100.0 (98.0–102.0) | 100.0 (98.0–102.0) | .143 |
| Total bilirubin (mg/dL) | 0.45 (0.23–0.65) | 0.50 (0.30–0.66) | 0.43 (0.23–0.55) | .005 |
| Direct bilirubin (mg/dL) | 0.22 (0.12–0.40) | 0.21 (0.12–0.44) | 0.22 (0.12–0.36) | .333 |
| Aspartate aminotransferase (IU/L) | 19.0 (16.0–29.0) | 19.0 (15.75–29.0) | 20.0 (16.0–27.0) | .747 |
| Alanine aminotransferase (IU/L) | 22.0 (16.0–28.0) | 22.0 (16.0–28.0) | 21.0 (15.0–29.0) | .844 |
| Gamma glutamyl transferase (IU/L) | 25.0 (18.0–41.0) | 25.0 (18.0–40.0) | 29.0 (19.0–44.0) | .089 |
| Alkaline phosphatase (IU/L) | 208.0 (156.0–255.5) | 207.0 (157.0–255.0) | 222.0 (127.0–265.0) | .219 |
Data are median (25th-75th percentile) except for mean (SD) corpuscular volume. P value calculated by Mann-Whitney U test.
Clinical data by histotype of esophageal carcinoma.
| Characteristics | All patients (n=1009) | Squamous cell carcinoma (n=834) | Adenocarcinoma (n=175) | |
|---|---|---|---|---|
| 50.0 (38.0–60.0) | 48.5 (36.0–60.0) | 55.0 (45.0–62.0) | <.001 | |
| Males (n=443) | 50.0 (42.0–62.0) | 50.0 (39.5–60.0) | 56.0 (46.0–62.0) | <.001 |
| Females (n=566) | 48.0 (35.0–59.0) | 46.0 (36.0–59.0) | 51.0 (35.0–60.0) | <.001 |
| Males | 443 (43.90%) | 306 (36.69%) | 137 (78.28%) | <.001 |
| Females | 566 (56.09) | 528 (63.30%) | 38 (21.71%) | |
| Proximal | 151 (15.0%) | 140 (16.8%) | 11 (6.3%) | <.001 |
| Middle | 246 (24.4%) | 213 (25.5%) | 33 (18.9%) | .061 |
| Distal | 366 (36.3%) | 290 (34.8%) | 76 (43.4%) | .030 |
| Proximal to middle | 48 (4.8%) | 40 (4.8%) | 8 (4.6%) | .899 |
| Proximal to distal | 12 (1.2%) | 11 (1.3%) | 1 (0.6%) | .703 |
| Middle to distal | 163 (16.2%) | 124 (14.9%) | 39 (22.3%) | .015 |
| From GEJ, extending into fundus | 4 (0.4%) | 1 (0.1%) | 3 (1.7%) | .018 |
| Unidentified | 19 (1.9%) | – | ||
| Ulcerated | 325 (32.2%) | 268 (32.1%) | 57 (32.6%) | .910 |
| Circumferential | 258 (25.6%) | 212 (25.4%) | 46 (26.3%) | .811 |
| Ulcerated circumferential | 72 (7.1%) | 50 (6.0%) | 22 (12.6%) | .002 |
| Nodular | 42 (4.2%) | 31 (3.7%) | 11 (6.3%) | .122 |
| Irregular | 123 (12.2%) | 112 (13.4%) | 11 (6.3%) | .009 |
| Polypoidal | 46 (4.6%) | 42 (5.0%) | 4 (2.3%) | .113 |
| Fungating | 57 (5.6%) | 43 (5.2%) | 14 (8.0%) | .138 |
| Stricture | 59 (5.8%) | 52 (6.2%) | 7 (4.0%) | .252 |
| Nodular and fungating | 7 (0.7%) | 7 (0.8%) | 0 (0.0%) | .612 |
| Unidentified | 20 (2.0%) | – | ||
| Present | 801 (79.4%) | 670 (80.3%) | 131 (74.9%) | .215 |
| Absent | 188 (18.6%) | 148 (17.7%) | 40 (22.9%) | |
| Unidentified | 20 (2.0%) | – | ||
Indicates Mann-Whitney U test used to compute the P value.
Indicates chi-square test to compute the P value.
Indicates Fisher's exact test to compute the p-value.
Radiological findings (n=1009).
| Characteristics | Squamous cell carcinoma (n=834) | Adenocarcinoma (n=175) | All patients (n=1009) | |
|---|---|---|---|---|
| Upper | 143 (17.1) | 13 (7.4) | .001 | 156 (15.5) |
| Middle | 207 (24.8) | 20 (11.4) | <.001 | 227 (22.5) |
| Lower | 288 (34.5) | 79 (45.1) | .008 | 367 (36.4) |
| Upper mid | 53 (6.4) | 15 (8.6) | .288 | 68 (6.7) |
| Upper lower | 8 (1.0) | 5 (2.9) | .058 | 13 (1.3) |
| Mid lower | 122 (14.6) | 39 (22.3) | .120 | 161 (16.0) |
| Unidentified | – | 17 (1.7) | ||
| Circumferential | 331 (39.7) | 100 (57.1) | <.001 | 431 (42.7) |
| Mural | 103 (12.4) | 16 (9.1) | .232 | 119 (11.8) |
| Both circumferential and mural | 317 (38.0) | 41 (23.4) | <.001 | 358 (35.5) |
| Eccentric | 60 (7.2) | 11 (6.3) | .669 | 71 (7.0) |
| Diffuse | 7 (0.8) | 2 (1.1) | .659 | 9 (0.9) |
| Unidentified | – | 21 (2.1) | ||
Data are number (%)
Chi-square test,
Fisher exact test
Histopathological variants (n=1009).
| Squamous Cell Carcinoma (n=834) | Adenocarcinoma (n=175) | ||
|---|---|---|---|
| Variant | Frequency | Variant | Frequency |
| Poorly differentiated SQC | 52 (6.2) | Poorly differentiated ADC | 41 (23.4) |
| Moderately differentiated SQC | 375 (45.0) | Moderately differentiated ADC | 38 (21.7) |
| Well differentiated SQC | 89 (10.7) | Well differentiated ADC | 27 (15.4) |
| Poorly differentiated and keratinized SQC | 6 (0.7) | Moderate to poorly differentiated ADC | 40 (22.8) |
| Moderately differentiated and keratinized SQC | 117 (14.0) | Moderate to well differentiated ADC | 8 (4.6) |
Data are number (%). SQC: Squamous cell carcinoma, ADC: Adenocarcinoma
Figure 1.Kaplan-Meier survival curves for histotype and differentiation of esophageal carcinoma.